Skip to content

Growing real-world evidence in cancer: How Sciensus can add value to pharmaceutical companies.

The number of cancer cases being diagnosed worldwide continues to rise, with the incidence of new cases predicted to increase from around 19 million in 2020 to 29 million by 2040. The disease was responsible for almost 10 million deaths in 2020, a number which is set to grow to 16 million by 2040.

The complexity of the disease itself and constraints on clinical trials means it can be difficult to get a clear picture of a new drug’s efficacy, safety and potential value in the open market.

Download this report to explore the ways in which real-world evidence (RWE), such as that collected by Sciensus, could help to close the gaps between clinical trial outcomes and clinical practice and improve care and outcomes for patients.